Leverage Shares 2x Micron Technology ETP Securities (2MU) News

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Reports Results of 2024 Annual General Meeting

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a...

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster...

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced...

Form D/A - Notice of Exempt Offering of Securities: [Amend]

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a...

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90...

Mainz Biomed Reports Full Year 2023 Financial Results

BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar...